Investigating a new treatment approach for glaucoma using GLP-1R agonists
Official title: Evaluating Mechanisms and Therapeutic Potential of (GLP-1R) Agonists for Glaucoma Treatment
Funded at University of Pennsylvania · NIH-11087540 · Data updated 2026-11-12
This study is looking at how a type of medication called GLP-1R agonists might help protect your eyesight by reducing inflammation in the eye for people with glaucoma, especially those who haven't found relief with standard treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 5, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $501,664 |
| NIH project number | 5R01EY034115-03 |
| Project ID | NIH-11087540 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with glaucoma who are experiencing progressive vision loss despite current treatments.
✕Less likely to help
Patients who have not been diagnosed with glaucoma or those whose vision loss is due to other unrelated conditions may not benefit from this research.
What this research studies
This research explores the potential of glucagon-like peptide-1 receptor (GLP-1R) agonists as a treatment for glaucoma, a condition that leads to vision loss due to the death of retinal ganglion cells. The study aims to understand how these agonists can protect against neurodegeneration by reducing inflammation in the retina. By examining the effects of GLP-1R agonists on microglia and macrophage activity, the researchers hope to identify mechanisms that could lead to new therapeutic strategies for patients who do not respond to traditional intraocular pressure-lowering treatments. If successful, this research could pave the way for innovative treatments that address the underlying causes of glaucoma.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for glaucoma patients that protects against vision loss without solely relying on lowering eye pressure.
How similar studies have gone: Previous studies have shown promising results with GLP-1R agonists in reducing glaucoma risk, indicating potential for success in this novel approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Cui, Qi N — University of Pennsylvania
- Study coordinator: Cui, Qi N
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Comparing tube positions in glaucoma implants to protect corneal cells
This trial compares two tube placements for glaucoma drainage implants to see which better protects corneal cells and controls eye pressure in people with uncontrolled glaucoma.
-
Automated topographic test for glaucoma detection and progression
A new automated method uses topographic structure-function mapping to help diagnose glaucoma earlier and track its progression in patients.
-
Using AI on eye scans and genes to predict glaucoma risk
This project uses artificial intelligence on eye scans, vision tests, and genetic information to find people most likely to develop or have worsening glaucoma.
-
AI-based glaucoma screening in community health centers
A new, easy-to-use AI screening approach will be tested in federally funded health centers to help identify people at risk for glaucoma, especially in communities with higher risk.
-
Understanding how glaucoma genes control eye cell function
A long-term research project will study how genetic factors affect eye cells in adults with glaucoma to uncover new ideas for protecting vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.